Amarin Corporation plc (AMRN) is a Biotechnology company in the Healthcare sector, currently trading at $14.55. It has a SharesGrow Score of 29/100, indicating a weak investment profile with 0 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of AMRN = $18.45 (+26.8% from the current price, the stock appears undervalued). Analyst consensus target is AMRN = $2 (-85.1% upside).
Valuation: AMRN trades at a trailing Price-to-Earnings (P/E) of -157.9 (S&P 500 average ~25).
Financials: revenue is $183M, -20.8%/yr average growth. Net income is $39M (loss), growing at +19.3%/yr. Net profit margin is -21.2% (negative). Gross margin is 66.1% (+0.4 pp trend).
Balance sheet: total debt is $12M against $459M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 3.34 (strong liquidity). Debt-to-assets is 1.8%. Total assets: $671M.
Analyst outlook: 3 / 18 analysts rate AMRN as buy (17%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 48/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 54/100 (Partial), Future 16/100 (Fail), Income 10/100 (Fail).
